REGEN
Get REGENGet Now
LibraryToolsNotesBlogFAQ

Oxytocin Dosage and Protocols

Oxytocin dosage protocols reported in published research, plus reconstitution and storage.

RE
Compiled from published research · Continuously updated

Intranasal Research Protocol

Research protocols commonly cite 20–40 IU intranasal, with 24 IU (6 sprays at 4 IU/spray) a frequently cited standard dose, administered 30–45 minutes before the target activity. Effects are reported to begin within 15–30 minutes and last roughly 2–4 hours. This is informal research-community convention, not an FDA-approved dosing schedule — the FDA-approved Pitocin dosing (for labor) is a completely separate, clinically-titrated IV protocol.

Reported protocol doses

Standard dose20–40 IU
Frequencyintranasal, pre-activity
Routesintranasal, subcutaneous, intravenous

Reconstitution

A 10mg vial with 2mL of bacteriostatic water is the pairing reported most often. Injectable/research vial form: a common convention is a 10mg (≈300 IU) vial reconstituted with bacteriostatic water. Intranasal research kits are typically pre-formulated by the vendor at a fixed IU/spray concentration.

Work out your own concentration with the reconstitution calculator.

Doses shown are those reported in published research, not a recommendation.

All Oxytocin sections

Thymosin Alpha-1

longevity & healthspanAgrade

A 28-amino-acid thymic peptide approved in 35+ countries as Zadaxin for immune support — but never FDA-approved in the United States.

SS-31 (Elamipretide)

longevity & healthspanBgrade

A mitochondria-targeting tetrapeptide, FDA-approved in September 2025 for Barth syndrome — a real approval in one narrow rare disease, not a general muscle or longevity drug.

Humanin

longevity & healthspanCgrade

A mitochondrial-derived peptide discovered protecting neurons from Alzheimer's-linked toxicity — cell and rodent data only, no human trial exists.

Put the whole protocol
in one place.

Download nowGet Now